BackHarvard Bioscience Overview

Harvard Bioscience Receivables

Harvard Bioscience's receivables is $15M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$14.57M
↑ 8.11% YoYΔ $1.09M vs prior year quarter

Peer average

Loading

Harvard Bioscience Receivables History

Loading

Harvard Bioscience vs. peers: Receivables Comparison

Loading

Harvard Bioscience Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Harvard Bioscience (HBIO) FAQ

The latest receivables for HBIO is $15M as of March 2026. That compares with $13M in the prior-year period — up 8.1% year over year. Investors often review this figure alongside Harvard Bioscience's historical trend and sector peers before judging valuation or financial health.

Over the past year, HBIO's receivables moved from $13M to $15M — a 8.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Harvard Bioscience's operating scale or balance-sheet position.

A receivables figure of $15M for HBIO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting HBIO's receivables ($15M), review year-over-year change from $13M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Harvard Bioscience's receivables against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.